权衡在中危前列腺癌放疗剂量递增基础上加用雄激素抑制疗法的利弊。 - Suppr

Suppr

超能文献

Weighing the Addition of Androgen Suppression Therapy to Radiotherapy Dose Escalation for Intermediate-Risk Prostate Cancer.

作者信息

Pollack Alan, Abramowitz Matthew C

机构信息

University of Miami Miller School of Medicine, Miami, FL

University of Miami Miller School of Medicine, Miami, FL.

出版信息

J Clin Oncol. 2016 May 20;34(15):1715-7. doi: 10.1200/JCO.2015.66.2320. Epub 2016 Mar 14.

DOI:10.1200/JCO.2015.66.2320

PMID:26976421

Abstract

摘要

相似文献

Weighing the Addition of Androgen Suppression Therapy to Radiotherapy Dose Escalation for Intermediate-Risk Prostate Cancer.

J Clin Oncol. 2016 May 20;34(15):1715-7. doi: 10.1200/JCO.2015.66.2320. Epub 2016 Mar 14.

Lack of benefit for the addition of androgen deprivation therapy to dose-escalated radiotherapy in the treatment of intermediate- and high-risk prostate cancer.

Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):1064-71. doi: 10.1016/j.ijrobp.2010.04.004. Epub 2010 Jun 26.

Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era?

Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):693-9. doi: 10.1016/j.ijrobp.2012.06.030. Epub 2012 Jul 24.

Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991.

J Clin Oncol. 2016 May 20;34(15):1748-56. doi: 10.1200/JCO.2015.64.8055. Epub 2016 Mar 14.

[Combined radiation therapy and androgen deprivation in the management of prostate cancer: Where do we stand?].

Cancer Radiother. 2016 Apr;20(2):141-50. doi: 10.1016/j.canrad.2015.12.002. Epub 2016 Mar 8.

Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.

Lancet Oncol. 2014 Sep;15(10):1076-89. doi: 10.1016/S1470-2045(14)70328-6. Epub 2014 Aug 14.

Survival outcomes of radiotherapy with or without androgen-deprivation therapy for patients with intermediate-risk prostate cancer using the National Cancer Data Base.

Urol Oncol. 2016 Apr;34(4):165.e1-9. doi: 10.1016/j.urolonc.2015.11.004. Epub 2015 Dec 11.

High-dose radiotherapy with or without androgen deprivation therapy for intermediate-risk prostate cancer: cancer control and toxicity outcomes.

Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):1473-9. doi: 10.1016/j.ijrobp.2011.10.036. Epub 2012 Jan 13.

The case for dose escalation versus adjuvant androgen deprivation therapy for intermediate risk prostate cancer.

Can J Urol. 2006 Apr;13 Suppl 2:68-71.

Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial.

Lancet Oncol. 2012 Dec;13(12):1260-70. doi: 10.1016/S1470-2045(12)70423-0. Epub 2012 Nov 12.

引用本文的文献

DNA Damage- But Not Enzalutamide-Induced Senescence in Prostate Cancer Promotes Senolytic Bcl-xL Inhibitor Sensitivity.

Cells. 2020 Jul 1;9(7):1593. doi: 10.3390/cells9071593.

Phase I Trial of MRI-Guided Prostate Cancer Lattice Extreme Ablative Dose (LEAD) Boost Radiation Therapy.

Int J Radiat Oncol Biol Phys. 2020 Jun 1;107(2):305-315. doi: 10.1016/j.ijrobp.2020.01.052. Epub 2020 Feb 19.

Effects of dose-escalated radiotherapy in combination with long-term androgen deprivation on prostate cancer.

Br J Radiol. 2018 Feb;91(1083):20170431. doi: 10.1259/bjr.20170431. Epub 2017 Dec 5.

High-dose radiotherapy with helical tomotherapy and long-term androgen deprivation therapy for prostate cancer: 5-year outcomes.

J Cancer Res Clin Oncol. 2016 Jul;142(7):1609-19. doi: 10.1007/s00432-016-2173-9. Epub 2016 May 2.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验